| 7.04 -0.57 (-7.49%) | 08-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.84  |
1-year : | 3.17 |
| Resists | First : | 2.43 |
Second : | 2.72 |
| Pivot price | 2.39 |
|||
| Supports | First : | 1.97 |
Second : | 1.63 |
| MAs | MA(5) : | 2.27 |
MA(20) : | 2.39 |
| MA(100) : | 2.38  |
MA(250) : | 2.02 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 8 |
D(3) : | 19.6 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 17.75 | Low : | 0.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ATNF ] has closed below the lower bollinger band by 17.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ATNF ] is to continue within current trading range. It is unclear right now based on current values. 77.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.23 - 2.25 | 2.25 - 2.26 |
| Low: | 1.93 - 1.95 | 1.95 - 1.97 |
| Close: | 1.97 - 2 | 2 - 2.02 |
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Mon, 18 Aug 2025
Thiel-backed Ethereum treasury fund ETHZilla completes rebrand as it continues ETH accumulation, deployment strategy - The Block
Mon, 18 Aug 2025
ETHZilla begins trading under new ticker ETHZ, holds $419 million in ETH - Investing.com
Mon, 18 Aug 2025
ETHZilla Unveils New Brand Committed to Advancing Ethereum Treasury Strategy - PR Newswire
Thu, 14 Aug 2025
180 Life Sciences Rebrands to ETHZilla Corporation - The Globe and Mail
Wed, 13 Aug 2025
AI for investors - MLQ.ai
Tue, 12 Aug 2025
Massive Crypto Move: ETHZilla Acquires 82,186 ETH at $3,806 Average, Reveals $587M War Chest - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 153 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 9.9 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 1,140 (K) |
| Shares Short P.Month | 64 (K) |
| EPS | -14.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -55.5 % |
| Return on Equity (ttm) | -371.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.14 |
| PEG Ratio | 0 |
| Price to Book value | 2.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -96.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|